Supplementary Materials
This PDF file includes:
- Fig. S1. Safety and efficacy profile of CRMP-treated, high-fat, fructose-fed cynomolgus macaques.
- Fig. S2. Oral CRMP dose escalation study in dysmetabolic rhesus macaques.
- Fig. S3. Plasma DNP concentrations in dysmetabolic rhesus macaques.
- Fig. S4. CRMP treatment does not alter oxidative stress in dysmetabolic rhesus macaques.
- Fig. S5. CRMP treatment does not alter whole-body glucose tolerance in dysmetabolic rhesus macaques.
- Fig. S6. Hepatic mitochondrial fluxes in dysmetabolic rhesus macaques treated with CRMP.
